Parataxis Holdings LLC has entered into an agreement to acquire a controlling interest in Bridge Biotherapeutics for KRW 25 billion ($18.3 million), establishing South Korea’s first Bitcoin treasury company, Parataxis Korea. The transaction will allow Bridge to maintain its biotech operations while integrating a Bitcoin treasury strategy, reflecting a growing institutional interest in the region. The deal is expected to close following shareholder approval in August 2025, with Andrew Kim assuming the CEO role.